United Therapeutics Corp (UTHR): Martine A Rothblatt , Chairman & CEO of United Therapeutics Corp sold 1,284 shares on Jul 21, 2016. The Insider selling transaction was reported by the company on Jul 22, 2016 to the Securities and Exchange Commission. The shares were sold at $113.46 per share for a total value of $144,790.78 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 15, 2016, Martine A Rothblatt (Chairman & CEO) sold 1,292 shares at $110.24 per share price.On Jun 10, 2016, Raymond Dwek (director) sold 3,000 shares at $166.28 per share price.Also, On Jun 9, 2016, Tommy G Thompson (director) sold 2,000 shares at $115.62 per share price.On Nov 4, 2015, Richard Giltner (director) sold 7,500 shares at $153.22 per share price.
United Therapeutics Corporation: On Wednesday, Jul 20, 2016 heightened volatility was witnessed in United Therapeutics Corporation which led to swings in the share price. The shares opened for trading at $112 and hit $115.12 on the upside , eventually ending the session at $114.83, with a gain of 3.57% or 3.96 points. The heightened volatility saw the trading volume jump to 6,76,726 shares. The 52-week high of the share price is $180.3999 and the company has a market cap of $5,124 M . The 52-week low of the share price is at $97.52.
Company has been under the radar of several Street Analysts.United Therapeutics Corporation is Downgraded by H.C. Wainwright to Neutral while Lowering the Price Target of the company shares to $ 95 from a previous price target of $175 . Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jun 15, 2016.United Therapeutics Corporation is Downgraded by Ladenburg Thalmann to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 29, 2016.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.